These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15374707)

  • 21. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
    Strickler R; Stovall DW; Merritt D; Shen W; Wong M; Silfen SL
    Obstet Gynecol; 2000 Sep; 96(3):359-65. PubMed ID: 10960626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene treatment increases plasma levels of beta-endorphin in postmenopausal women: a randomized, placebo-controlled study.
    Neele SJ; Evertz R; Genazzani AR; Luisi M; Netelenbos C
    Fertil Steril; 2002 Jun; 77(6):1110-7. PubMed ID: 12057714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women.
    Palomba S; Sammartino A; Di Carlo C; Affinito P; Zullo F; Nappi C
    Fertil Steril; 2001 Jul; 76(1):38-43. PubMed ID: 11438317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.
    Voss S; Quail D; Dawson A; Bäckström T; Aguas F; Erenus M; The HS; Bonnar J; De Geyter C; Hunter M; Nickelsen T;
    BJOG; 2002 Aug; 109(8):874-85. PubMed ID: 12197366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
    Duschek EJ; de Valk-de Roo GW; Gooren LJ; Netelenbos C
    Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity.
    Reindollar R; Koltun W; Parsons A; Rosen A; Siddhanti S; Plouffe L;
    Fertil Steril; 2002 Sep; 78(3):469-72. PubMed ID: 12215319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
    Vila È; Huerta-Ramos E; Núñez C; Usall J; Ramos B
    Eur Arch Psychiatry Clin Neurosci; 2019 Dec; 269(8):941-948. PubMed ID: 30167782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
    Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
    J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women.
    Endrikat J; Lange E; Kunz M; Schmidt W; Graeser T
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):229-39. PubMed ID: 17763261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study.
    Paoletti AM; Cagnacci A; Di Carlo C; Orrù MM; Neri M; D'Alterio MN; Melis GB
    Gynecol Endocrinol; 2015 May; 31(5):384-7. PubMed ID: 25703254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
    Samsioe G; Hruska J;
    Climacteric; 2010 Feb; 13(1):34-44. PubMed ID: 20001563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
    Colacurci N; Fornaro F; Cobellis L; De Franciscis P; Torella M; Sepe E; Arciello A; Cacciapuoti F; Paolisso G; Manzella D
    Menopause; 2007; 14(5):879-84. PubMed ID: 17667145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
    Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
    BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
    Engin-Ustün Y; Ustün Y; Meydanli MM; Kafkasli A
    Gynecol Endocrinol; 2006 Dec; 22(12):676-9. PubMed ID: 17162709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
    Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
    Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.